Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
3(43%)
Results Posted
200%(2 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
5
71%
Ph early_phase_1
1
14%
Ph phase_2
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Recruiting2
Active, not recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 15 (71.4%)
Phase 21 (14.3%)

Trials by Status

terminated229%
active_not_recruiting114%
recruiting229%
completed114%
not_yet_recruiting114%

Recent Activity

3 active trials
Showing 5 of 7
not_yet_recruitingphase_2

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

NCT07508787
terminatedphase_1

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
terminatedphase_1

Siplizumab in T1DM

NCT05574335
active_not_recruitingphase_1

Delayed Tolerance Through Mixed Chimerism

NCT05900401
recruitingphase_1

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07508787Phase 2

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Not Yet Recruiting
NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated
NCT05574335Phase 1

Siplizumab in T1DM

Terminated
NCT05900401Phase 1

Delayed Tolerance Through Mixed Chimerism

Active Not Recruiting
NCT06455280Phase 1

A Study of SIPLIZUMAB in AILD and LT Patients

Recruiting
NCT06326476Early Phase 1

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

Recruiting
NCT01445535Phase 1

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7